Currently out of the existing stock ratings of Nigel Dally, 61 are a SELL (12.79%), 256 are a HOLD (53.67%), 160 are a BUY (33.54%).

Nigel Dally

Work Performance Price Targets & Ratings Chart

Analyst Nigel Dally, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 79.38% that have a potential upside of 40.1% achieved within 346 days.

Nigel Dally’s has documented 918 price targets and ratings displayed on 24 stocks. The coverage is on Financial Services, Healthcare, Communication Services, Basic Materials sectors.

Most recent stock forecast was given on MET, MetLife at 05-Jul-2026.

Wall Street Analyst Nigel Dally

Analyst best performing recommendations are on ARQT (ARCUTIS BIOTHERAPEUTICS ).
The best stock recommendation documented was for ARQT (ARCUTIS BIOTHERAPEUTICS ) at 11/13/2023. The price target of $10 was fulfilled within 106 days with a profit of $7.89 (373.93%) receiving and performance score of 35.28.

Average potential price target upside

of $31.72 (16.67%) on AMP (AMERIPRISE FINANCIAL).
of $28.99 (41.99%) on PRU (PRUDENTIAL FINANCIAL).
of $18.15 (15.62%) on PRI (PRIMERICA).

AFL Aflac AMP Ameriprise Financial ATH Athene Holding Ltd BHF Brighthouse Financial CNO CNO Financial Group EQH Axa Equitable Holdings GL Globe Life GNW Genworth Financial JXN Jackson Financial LNC Lincoln National MET MetLife MFC Manulife Financial Corp PFG Principal Financial Group RGA Reinsurance Group of America UNM Unum Group VOYA Voya Financial AEL American Equity Investment Life Holding Co PRU Prudential Financial CRBG Corebridge Financial ARQT Arcutis Biotherapeutics ATEX Anterix ICL ICL Israel Chemicals Ltd MOS The Mosaic Company PRI Primerica

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Wesley Carmichael (WELLS FARGO)